X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/neurosense-and-genetika-initiate-precision-medicine-collaboration-beginning-with-ongoing-phase-2-clinical-trial-in-alzheimers-disease-302122778.html
https://www.prnewswire.com/news-releases/neurosense-to-present-paradigm-data-at-the-american-academy-of-neurology-annual-meeting-april-16-2024-302115365.html
https://www.prnewswire.com/news-releases/neurosense-announces-pricing-of-4-5-million-registered-direct-offering-and-concurrent-private-placement-302113720.html
https://www.contractpharma.com/contents/view_breaking-news/2024-04-09/lonza-neurosense-enter-alliance-for-als-candidate/
https://www.prnewswire.com/news-releases/neurosense-collaborates-with-lonza-to-identify-exosome-based-biomarkers-in-order-to-advance-neurodegenerative-disease-treatments-and-diagnostics-302111745.html
https://www.prnewswire.com/news-releases/neurosense-announces-year-end-2023-financial-results-and-provides-business-update-302109196.html
https://www.prnewswire.com/news-releases/neurosense-reports-additional-positive-results-from-its-als-phase-2b-paradigm-trial-302067299.html
https://www.prnewswire.com/news-releases/neurosense-regains-compliance-with-nasdaq-minimum-bid-price-rule-302056171.html
https://www.prnewswire.com/news-releases/neurosenses-phase-2b-als-trial-achieves-primary-safety-and-tolerability--secondary-clinical-efficacy-endpoints-302005837.html
https://www.prnewswire.com/news-releases/neurosense-to-report-phase-2b-als-topline-primary-safety-and-tolerability--secondary-clinical-efficacy-endpoints-on-december-5-2023-302005044.html
Market Place
Share 
